COMMUNICATION

COM-2024-051

1 August 2024

PLEASE REVIEW

Drug Information

PharmPix Clinical Department

PharmPix is committed to the health and wellness of our members.

The clinical team wants to communicate the latest up-to-date drug information requested.

Drug Information:

Remember that medical literature is dynamic and is continuously changing as new scientific knowledge is developed. We exhort the frequent revision of treatment guidelines to assure that your recommendations are consistent with the most updated information.

It is our priority to offer high-quality services and support practices for health promotion and disease prevention. If you have any questions or wish to have more information regarding this document, you can call us directly or view PharmPix communications online.

QUESTIONS

Call us at 787-522-5252, ext. 219.

Access our recent communications at our providers' portal: https://www.pharmpix.com/providers/.

FDA Approves Kisunla for Early Alzheimer's Treatment

The U.S. Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt) for the treatment of early symptomatic Alzheimer's disease, marking a significant advancement in the fight against this progressive condition.

Kisunla Overview:

Kisunla (donanemab-azbt) is a monoclonal antibody approved by the FDA on July 2, 2024, for the treatment of adults with early symptomatic Alzheimer's disease (AD), which includes patients with mild cognitive impairment and mild dementia. Kisunla works by targeting amyloid plaques in the brain, which are a hallmark of Alzheimer's disease. Kisunla is administered as an intravenous infusion once a month. Kisunla is the second Alzheimer's drug of its kind approved, the first one being Leqembi.

Efficacy, Safety, and Impact

The efficacy of Kisunla was demonstrated in the phase 3 TRAILBLAZER-ALZ 2 trial, where it significantly slowed the progression of Alzheimer's disease. Patients treated with Kisunla showed a 35% slower decline in cognitive and functional abilities compared to those on a placebo. Additionally, Kisunla reduced amyloid plaques by 61% at 6 months, 80% at 12 months, and 84% at 18 months from the baseline. However, the drug can cause amyloid-related imaging abnormalities (ARIA), a potential side effect that is generally asymptomatic and detectable via MRI.

If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252-ext 219. Our pharmacists will help you. In addition, know that you can access our recent communications at our providers' portal: https://www.pharmpix.com/providers/.

pharmpix
POWERED BY ONEARK

REFERENCES:
1. Myshko, D. (2024, July 2). FDA approves Lilly's alzheimer's disease drug. Managed Healthcare Executive. https://www.managedhealthcareexecutive.com/view/fda-approves-lilly-s-alzheimer-s-disease-drug
2. Kisunla (donanemab-AZBT) injection, for intravenous use. (n.d.). https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761248s000lbl.pdf
3. Alzheimer's disease fact sheet | National Institute on Aging. (n.d.-a). https://www.nia.nih.gov/health/alzheimers-and-dementia/alzheimers-disease-fact-sheet

urac ACCREDITED Pharmacy Benefit Management Expires 12/01/2025

2 Street 1, Suite 500
Guaynabo, PR 00968

Tel. 787.522.5252
Fax 866.912.2830

www.pharmpix.com
FRM-CL-000130-001

CLINICAL PEARLS BY PHARMPIX